CAR-T Therapy for Marginal Zone Lymphoma

Marginal zone lymphoma (MZL) is a heterogeneous subtype of B-cell non-Hodgkin’s lymphoma. Although most patients have a prolonged indolent clinical course, some experience multiple relapses and shorter survival. Researchers now report results from a phase 2 multicenter industry-sponsored trial for patients with relapsed or refractory MZL who were treated with a single infusion of autologous anti-CD19 lisocabtagene maraleucel (liso-cel) chimeric antigen receptor T-cell (CAR-T) therapy. Sixty-seven patients with nodal, extranodal, or splenic MZL (median age, 62) and at least two prior lines of therapy (median, 3) were treated; 30 patients (45%) received bridging therapy before CAR-T infusion.